---
title: "Spyre Therapeutics CEO Turtle Cameron disposes of 15,000 common shares worth $1.31 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297975740.md"
description: "Spyre Therapeutics CEO Turtle Cameron sold 15,000 common shares on September 1, 2026, at an average price between $86.36 and $89.07, totaling approximately $1.31 million. Following this transaction, Cameron's direct shareholding decreased to 552,540 shares. The information was published via EDGAR by Spyre Therapeutics Inc."
datetime: "2026-09-04T01:33:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297975740.md)
  - [en](https://longbridge.com/en/news/297975740.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297975740.md)
generator: "portal-rs"
---

# Spyre Therapeutics CEO Turtle Cameron disposes of 15,000 common shares worth $1.31 million

-   Spyre Therapeutics CEO Turtle Cameron sold 15,000 common shares on Sep. 1, 2026 at weighted-average prices of USD 86.36 to USD 89.07. \* Cameron’s direct holding fell to 552,540 shares following the transactions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001636282-26-000107), on September 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [SYRE.US](https://longbridge.com/en/quote/SYRE.US.md)

## Related News & Research

- [Spyre reports positive Phase 2 SKYLINE Part A induction data for UC drug SPY003, hits primary endpoint](https://longbridge.com/en/news/298315418.md)
- [Insider Selling: Spyre Therapeutics (NASDAQ:SYRE) Insider Sells $36,000.00 in Stock](https://longbridge.com/en/news/297984230.md)
- [Iguatemi board member cuts IGTI11 units stake by R$ 1.3 million in August sales](https://longbridge.com/en/news/298662019.md)
- [Orizon controller stake slips by R$ 62,693 on August spot share sales](https://longbridge.com/en/news/298657288.md)
- [Alpargatas advisory board cuts stake by R$ 19,650 on cash-market sale](https://longbridge.com/en/news/298367212.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**